# Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy

> **NCT05575986** · PHASE4 · UNKNOWN · sponsor: **Huazhong University of Science and Technology** · enrollment: 40 (estimated)

## Conditions studied

- Malignant Tumors of the Digestive System
- Trombocitopenia

## Interventions

- **DRUG:** Hetrombopag Olamine

## Key facts

- **NCT ID:** NCT05575986
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2023-10
- **Final completion:** 2023-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05575986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05575986, "Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05575986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*